Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2017-18 | Page 72

### Cash Flows from Operating Activities

| Particulars | Notes | Amount in Taka |
| --- | --- | --- |
| Receipts from Customers and Others |  | 17,195,399,333 |
| Payments to Suppliers and Employees |  | (14,113,012,465) |
| Cash Generated from Operations |  | 3,082,386,868 |
| Interest Paid |  | (536,570,775) |
| Interest Received |  | 54,928,425 |
| Income Tax Paid |  | (781,630,595) |
| Net Cash Generated from Operating Activities | 35 | 1,819,113,923 |

### Cash Flows from Investing Activities

| Particulars | Notes | Amount in Taka |
| --- | --- | --- |
| Acquisition of Property, Plant and Equipment |  | (4,951,352,340) |
| Intangible Assets |  | (106,921,036) |
| Acquisition of Subsidiary |  | (2,125,186,000) |
| Disposal of Property, Plant and Equipment |  | 14,114,722 |
| Dividend Received |  | 1,504,092 |
| Decrease in Short Term Investment |  | 547,179,732 |
| Net Cash Used in Investing Activities |  | (6,620,660,830) |

### Cash Flows from Financing Activities

| Particulars | Notes | Amount in Taka |
| --- | --- | --- |
| Net Increase in Long Term Borrowings |  | 1,859,021,877 |
| Net Increase in Short Term Borrowings |  | 3,546,896,539 |
| Dividend Paid |  | (502,757,959) |
| Net Cash Generated from Financing Activities |  | 4,903,160,457 |
| Increase in Cash and Cash Equivalents |  | 101,613,550 |
| Cash and Cash Equivalents at Beginning of Year |  | 292,122,396 |
| Cash and Cash Equivalents at End of Year | 14 | 393,735,946 |
| Net Operating Cash Flow Per Share | 34 | 4.49 |